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Abstract
Objectives: Changes in the prevalence of faecal occult blood test positivity over 
time have not been previously reported, but could have important implications. This 
study has examined the positivity of the initial guaiac faecal occult blood test 
(gFOBT), a surrogate marker for colorectal bleeding, in 50-year-old participants in a 
national bowel screening programme.
Setting: Scottish Bowel Screening Programme.
Methods: Data from the Scottish Bowel Screening Programme (SBoSP) were used 
to study the initial positivity of the gFOBT between 2007 and 2017. In addition, the 
positive predictive values (PPV) of the testing process for colorectal cancer (CRC) 
and adenoma were assessed over the same time period.
Results: Across Scotland, the initial gFOBT positivity increased from 4.1% to 10.8% 
and, in NHS Grampian and NHS Fife, two of the three NHS Boards which began roll-
out of screening in 2007, it increased from 4.0% to 10.9%. In the SBoSP, the PPV for
CRC declined from 11.0% to 6.6% and for adenoma it increased from 31.6% to 
39.8%. 
Conclusions: Over a decade, initial gFOBT positivity increased in 50-year-old 
participants in the SBoSP.  This may be associated with changes in lifestyle and 
might have implications for screening clinical outcomes, including PPV.
Introduction
In many countries, regular testing for the presence of occult blood in faeces is used 
for colorectal cancer (CRC) screening,1 but how the prevalence of detectable blood 
in faeces changes over time has not been rigorously documented.  This is important 
for several reasons.  Firstly, if there is a change in the background prevalence of 
faecal occult blood test positivity, this could have an impact on the positive predictive
value (PPV) of screening using this modality.  Secondly, changes in test positivity 
have implications for service provision in terms of endoscopy capacity. Thirdly, we 
have recently shown that a positive gFOBT result is associated with premature 
mortality from all causes, independent of its association with risk of death from 
CRC,2 so that changes in gFOBT positivity may act as an index of possible changes 
in mortality. To assess changes in gFOBT positivity, this study examined the results 
of the initial guaiac faecal occult blood test (gFOBT), a surrogate marker for 
colorectal bleeding, over a decade in 50-year-old participants in a national bowel 
screening programme.
Methods
In Scotland, CRC screening using a guaiac faecal occult blood (gFOBT) as the first-
line investigation was piloted over three screening rounds in three NHS Boards 
(Tayside, Grampian and Fife) from 2000 to 2007.  The Scottish Bowel Screening 
Programme (SBoSP) was rolled out to the rest of Scotland between June 2007 and 
December 2009.  The algorithm used in the SBoSP differed from those used in the 
pilot screening rounds, and the details have been described elsewhere3 but, 
basically, it consisted of an initial guaiac-based FOBT (gFOBT) where the invitees 
were asked to provide a total of six faecal samples (two from each of three separate 
bowel movements) on cards with a window for each sample, followed by a card-
based qualitative faecal immunochemical test for haemoglobin (FIT) if one to four 
windows gave a positive result on the initial gFOBT, a “weak positive” result.  If five 
or six windows were positive on the initial gFOBT or the qualitative FIT was positive, 
colonoscopy was offered immediately.  This two-tier reflex gFOBT/FIT algorithm 
continued until November 2017 when it was replaced by a single faecal sample 
quantitative FIT.4 All samples were analysed in the Scottish Bowel Screening 
Laboratory which holds ISO 15189 accreditation. The Laboratory performed 
comprehensive internal quality control, including assessment of individual screener 
staff performance, both analytically and through monitoring of positivity reported. 
Since gFOBT requires visual interpretation of the colours on the test card, all positive
test results were confirmed by a second screener. External quality assessment was 
undertaken through participation in the United Kingdom National External Quality 
Assessment Scheme (UKNEQAS).  Acceptance quality checks were undertaken for 
all new manufacturing lots of gFOBT and FIT.5 There were no significant changes in 
the testing processes, faecal test characteristics, or gFOBT manufacturer and 
supplier, from 2000 to 2017. The instructions given to participants did not change 
during the study: no dietary restrictions, including vitamin C intake, nor cessation of 
medicines such as non-steroidal anti-inflammatory drugs and anti-coagulants, were 
advocated.
Estimation of changes in gFOBT positivity over time using data from the SBoSP is 
not straightforward.  Firstly, if all results were used, the data would comprise a 
mixture of prevalence (first time) and incidence (repeat) screening and from 
participants of a range of ages between 50 and 74 years, the proportions of which 
changes over time.  Since it is known that the gFOBT positivity in incidence 
screening is less than that of prevalence screening6 and increases with age,7 it would
be difficult to disentangle these effects from a true change in gFOBT positivity in the 
whole population accepting screening.  Secondly, since the SBoSP was being rolled 
out between 2007 and 2009, and the effect of adding a screening naive NHS Board 
takes two years (a single screening round) to be complete, the screened population 
has only been geographically stable since the end of 2011.  Since the gFOBT 
positivity varies considerably between NHS Boards,8 possibly as a result of varying 
degrees of socio-economic deprivation, this adds another effectively uncontrollable 
variable.  Thirdly, since the final result in the context of the SBoSP, up until 
November 2017, is derived from an algorithm that, by design, cuts-down the overall 
positivity and minimises false positive results by excluding a high proportion of those 
participants who exhibit lower (weak) degrees of positivity on the initial gFOBT (only 
a small proportion of those with one to four windows positive on this initial gFOBT 
have a positive FIT result3),  using the overall final result of the screening algorithm to
assess variation in gFOBT positivity over time would underestimate any changes.
For these reasons, this study examined the overall positivity of only the initial gFOBT,
not the final positivity of the overall screening algorithm, that is, the positivity in those
who had any one or more windows positive, but only in 50-year-old participants. This
ensured that all subjects in this study were the same age and were undergoing only 
prevalence screening.  This initial gFOBT positivity was determined for every year 
from 2007 to 2017 for the whole of Scotland and, to eliminate the possible effect of 
adding different NHS Boards during roll-out of the SBoSP, an additional analysis was
carried out restricted to NHS Grampian and NHS Fife; along with NHS Tayside, 
these two NHS Boards were the first to participate in the roll-out of the SBoSP in 
2007, having taken part in the three pilot screening rounds from 2000 to 2007.6  
However, NHS Tayside performed an evaluation of quantitative FIT as the first-line 
screening test between 01 July 2010 and 31 December 2010,9 and was therefore 
excluded from the analysis since, during this time, this could have introduced a 
spurious fluctuation in positivity.
The data for these analyses were obtained from the Bowel Screening Database held
by the Information Services Division (ISD) of National Services Scotland (NSS). Data
from the pilot screening rounds could not be studied, since the overall positivity rate 
of the initial gFOBT was not recorded, only the final outcome of the screening 
algorithms used in these three rounds. Formal ethical approval for the study was not 
required since individual participants were not approached and only routinely 
collected data were used.  Researchers wishing to access these data can apply for 
permission via the ISD’s Electronic Data, Research and Innovation Service 
(NSS.eDRIS@nhs.net).  
Results
For the whole of Scotland, there was a steady rise in gFOBT positivity (i.e., any 
positive window on the initial gFOBT card) in 50-year-old participants from 4.1% 
(95% confidence intervals [CI]: 3.7 - 4.6) in 2007 to 10.8% (95% CI: 10.3 - 11.3) in 
2017 (Figure 1). In NHS Grampian and NHS Fife (Figure 2) a similar rise was seen: 
4.0% (95% CI: 3.5 - 4.6) to 10.9% (95% CI: 9.7 - 12.1). As evidenced by the wide 
separation of the higher confidence intervals for the 2007 data and the lower 
confidence intervals for the 2017 data, these differences were highly statistically 
significant (p<0.00001 by X2 testing in both instances). Positivity rates for women 
were lower than that for men, as has been found previously overall in the SBoSP,7 
although these did converge in 2017 in NHS Grampian and NHS Fife.
For completeness, the final results of the screening algorithm (derived from the 
gFOBT/FIT two-tier reflex approach) were also examined, and the positivity in those 
aged 50 years for the whole of Scotland increased from 0.68% (95% CI: 0.53 - 0.88) 
to 1.6% (95% CI: 1.4 - 1.7) (p < 0.00001 by X2 testing) between 2007 and 2017. This
supports the view that the rise in initial gFOBT positivity was indeed due to the 
presence of occult blood in faeces and not to other moieties, since these would not 
be detected by the qualitative FIT used to determine the need for further 
investigation in those participants with one to four windows (weak) positive, since the
qualitative FIT used is based upon the reaction with antibodies specific to the globin 
moiety of human haemoglobin.
Since a change in background gFOBT positivity could affect the positive predictive 
value (PPV) for neoplasia, the PPV for both CRC and adenoma over time were also 
examined. By necessity, this had to be calculated on the basis of those who had a 
final positive test result based on the whole screening algorithm, but as described in 
the preceding paragraph the positivity derived in this way has also increased during 
the study period.  Between 2007 and 2017 the PPV for CRC fell from 11.0% to 6.6% 
(p<0.00001 by X2 testing) as shown in Figure 3 and for adenoma it increased from 
31.6% to 39.8% (p<0.00001 by X2 testing) as shown in Figure 4.  
Discussion
To our knowledge, this is the first time that the change over time of faecal occult 
bleeding, as inferred from initial gFOBT positivity, has been reliably investigated.  It is
true that gFOBT provide an indirect measure of gastrointestinal, particularly 
colorectal, bleeding since it is based on a chemical reaction that can give false 
positive results from peroxidase containing materials in the diet and dietary 
restriction was not mandated in the SBoSP.  However, there is evidence that, when 
gFOBT cards are allowed to dry for some days prior to development in the 
laboratory, as was the case in the SBoSP, such dietary effects are negligible.10,11
Using FIT would clearly provide a more secure estimate of the presence of occult 
blood in faeces, but there are no screening programmes using this approach that are
of sufficient duration to study the change in faecal haemoglobin concentration over 
time.  However, this will be interesting to study in the future, both in the nations of the
UK and other countries, especially as FIT is now replacing gFOBT world-wide. 
The reason behind this highly likely increase in faecal occult bleeding in the 
population studied is not clear, but it is noteworthy that our recent study of gFOBT 
results and all-cause mortality showed that a positive gFOBT result was associated 
with an increase in all-cause mortality, in all non-CRC mortality and in death from a 
variety of chronic conditions including cardiovascular disease, respiratory disease 
and cancer excluding CRC.2  In this study, it was demonstrated that this effect was 
independent of medicines that could cause bleeding, such as anti-coagulants and 
aspirin and other non-steroidal anti-inflammatory medicines, and the hypothesis was 
generated that a positive gFOBT result, implying gastrointestinal bleeding, might 
reflect systemic inflammation caused in turn by factors predisposing to ill health, 
such as obesity,12,13 sedentary behavior,14,15 smoking,16 alcohol dependence17 and a 
“Western” diet.18,19 
Thus, the rise in initial gFOBT positivity seen in the ten-year interval between 2007 
and 2017 could be related to changing lifestyle factors. Trends data from the Scottish
Health Survey from 2008 to 2017 report less than ideal levels of physical activity, fruit
and vegetable intake, alcohol, smoking and obesity in adult men and women aged 
45 to 54 years.20 However, it is notable that the only lifestyle risk factor which has 
increased during this time in this age group is obesity (from 30% to 36% prevalence 
in men and 29% to 34% prevalence in women) which, given that physical activity has
increased, implies that caloric intakes have increased. Obesity per se is associated 
with increased inflammation and changes in the microbiota,21 which might in turn 
influence gFOBT results.  It is also of interest of note that, in Scotland, average life 
expectancy is beginning to decline,22 which is in keeping with our observations. 
The hypothesis that faecal haemoglobin concentrations are a reflection of systemic 
inflammation could be addressed by carrying out a similar study using faecal 
calprotectin, or possibly other markers of inflammation, but this is impractical given 
the time scales involved.  It is relevant to note, however, that in our study of gFOBT 
positivity and all-cause mortality, a number of non-neoplastic causes of death known 
to be associated with systemic inflammation were also associated with a positive 
gFOBT result.2
Quite apart from any public health implications of this observation, an increase in the
background rate of faecal occult bleeding that is unrelated to the incidence of CRC 
could impact on the overall performance of a population-based programmatic CRC 
screening programme predicated on the detection of the presence of occult blood in 
faeces through decreasing the positive predictive value (PPV) of the test result. In 
the SBoSP, the PPV of a final test result for both CRC and adenoma have been key 
performance indicators (KPI) since the beginning of the SBoSP.7 Examination of the 
PPV for CRC over time demonstrated that there was indeed a decline in the PPV 
between 2007 and 2017 from 11.0% to 6.6% leading to a small decrease in cancer 
detection rate in those with a final screening test result,7 albeit accompanied by an 
increase in overall uptake, as has been described in detail.23 This could be explained
by a decrease in the ratio of prevalence to incidence screening episodes or changes 
in colonoscopy quality, although in Scotland, as we have described,24 no new 
measures were introduced to improve or audit colonoscopy performance throughout 
the study periods.  However, an increase in background population gFOBT positivity 
is an alternative or additional explanation and this could be interpreted as an 
inherent weakness of this approach to screening.
However, the PPV for adenoma increased between 2007 and 2017 from 31.6% to 
39.8%.  This is in keeping with the hypothesis that adenomas are detected by tests 
for the presence of occult blood in faeces, not simply because they bleed, but 
because chronic inflammation is involved in the initiation of the neoplastic process so
that adenomas tend to arise in a sub-clinically inflamed colon.  If this is the case, an 
increase in faecal occult bleeding in the population might signal an increase in the 
incidence of colorectal adenomas.  Thus, testing for the presence of occult blood in 
faeces might prove to be an effective means of finding adenomas that will take 
account of changes in incidence, especially if the faecal haemoglobin concentration 
threshold for triggering a colonoscopy from quantitative FIT is lowered.  This in turn 
could enhance the ability of screening programmes to prevent the development of 
invasive CRC by interrupting the adenoma-carcinoma sequence.
Conclusions
Over a decade, initial gFOBT positivity increased in 50-year-old participants in the 
SBoSP.  This may be associated with changes in lifestyle and might have 
implications for screening clinical outcomes, including PPV.
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Figure 1.  Change in the positivity of the initial gFOBT in 50-year-old participants 
in the Scottish Bowel Screening Programme between 2007 and 2017 for the 
whole of Scotland. (X2= 305.6 p<0.00001).
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Figure 2. Change in the positivity of the initial gFOBT in 50-year-old participants 
in the Scottish Bowel Screening Programme between 2007 and 2017 from NHS 
Grampian and NHS Fife Boards only.  (X2= 115.1 p<0.00001).
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Figure 3.  Positive predictive value for colorectal cancer in the Scottish Bowel 
Screening Programme between 2007 and 2017 (X2=24.8 p<0.00001).
 
Figure 4.  Positive predictive value for adenoma in the Scottish Bowel Screening 
Programme between 2007 and 2017 (X2=23.4 p<0.0001).
